Journal: OncoImmunology

Article Title: MICA/B-targeted antibody promotes NK cell–driven tumor immunity in patients with intrahepatic cholangiocarcinoma

doi: 10.1080/2162402x.2022.2035919

Figure Lengend Snippet: Figure 6. Anti-MICA/B 7C6 mAb boosts anti-tumor cytotoxic function of peripheral NK cells from iCCA patients against the HuCCT-1 cell line. A): peripheral NK cell degranulation, evaluated as frequency of CD107a+ NK cells, in iCCA patients (n = 13) and HC (n = 16) in the presence of 7C6 mAb or IgG1-Fc. Parametric paired and unpaired t tests were used to compare data. B): dot plots showing the frequency of CD3-CD56+ CD107a+ NK cells in a HC and a patient (iCCA) in the presence of 7C6 mAb or IgG1-Fc. C): the proportion of circulating IFNγ+ NK cells in patients (n = 10) and HC (n = 11) in the presence of 7C6 mAb compared with IgG1-Fc. To compare paired data, the parametric t test and the non-parametric Wilcoxon t test were used. To compare unpaired data, the parametric t test and the non-parametric Mann-Whitney U test were used. D): representative dot plots showing the frequency of CD3-CD56+ IFNγ+ NK cells in a HC and in a patient (iCCA) in the presence of 7C6 mAb or IgG1-Fc.

Article Snippet: The recombinant human IgG1 Fc (BioXcell, Lebanon, NH, USA) and the humanized anti-MICA/B 7C6-IgG1 mAb were added at a final concentration of 10 μg/ml.

Techniques: MANN-WHITNEY

Journal: OncoImmunology

Article Title: MICA/B-targeted antibody promotes NK cell–driven tumor immunity in patients with intrahepatic cholangiocarcinoma

doi: 10.1080/2162402x.2022.2035919

Figure Lengend Snippet: Figure 7. Anti-MICA/B 7C6 mAb boosts anti-tumor cytotoxic function of peripheral NK cells from iCCA patients against patient-derived iCCA cell lines. A): peripheral NK cell degranulation, evaluated as CD107a+NK frequency, in iCCA patients (n = 12) and HC (n = 8) in the presence of 7C6 mAb or IgG1-Fc using patient- derived primary tumor cell lines as targets. Parametric paired and unpaired t tests were used to compare data. B): dot plots showing the frequency of CD3-CD56 + CD107a+ NK cells in a HC and in a patient (iCCA) in the presence of 7C6 mAb or IgG1-Fc. C): proportion of circulating IFNγ+NK cells in patients (n = 10) and in HC (n = 8) in the presence of 7C6 mAb compared with IgG1-Fc. To compare paired data, we used the parametric t test and the non-parametric Wilcoxon t test. To compare unpaired data, the parametric t test and the non-parametric Mann-Whitney U test were used. D): representative dot plots showing the frequency of CD3-CD56+ IFNγ +NK cells in a HC and in a patient (iCCA) in the presence of 7C6 mAb or IgG1-Fc.

Article Snippet: The recombinant human IgG1 Fc (BioXcell, Lebanon, NH, USA) and the humanized anti-MICA/B 7C6-IgG1 mAb were added at a final concentration of 10 μg/ml.

Techniques: Derivative Assay, MANN-WHITNEY

Journal: OncoImmunology

Article Title: MICA/B-targeted antibody promotes NK cell–driven tumor immunity in patients with intrahepatic cholangiocarcinoma

doi: 10.1080/2162402x.2022.2035919

Figure Lengend Snippet: Figure 8. 7C6 mAb enhances the anti-tumor effect of liver- and tumor-infiltrating NK cells in iCCA patients. A): Frequency of degranulating CD107a+NK cells in LIL (n = 13) and TIL (n = 10) of iCCA patients in the presence of anti-MICA/B 7C6 mAb or IgG1-Fc using autologous tumor-derived cell lines as targets. Parametric paired and unpaired t tests were used to compare data. B): representative dot plots showing the frequency of CD3-CD56+ CD107a+ LIL- and TIL-NK cells in the presence of 7C6 mAb or IgG1-Fc. C): proportion of IFNγ+ NK cells in LIL (n = 10) and TIL (n = 8) of iCCA patients in the presence of 7C6 mAb compared with IgG1-Fc using autologous tumor-derived cell lines as targets. The parametric t test and non-parametric Wilcoxon t test were used to compare paired data. The parametric t test was used to compare unpaired data.

Article Snippet: The recombinant human IgG1 Fc (BioXcell, Lebanon, NH, USA) and the humanized anti-MICA/B 7C6-IgG1 mAb were added at a final concentration of 10 μg/ml.

Techniques: Derivative Assay

Journal: OncoImmunology

Article Title: MICA/B-targeted antibody promotes NK cell–driven tumor immunity in patients with intrahepatic cholangiocarcinoma

doi: 10.1080/2162402x.2022.2035919

Figure Lengend Snippet: Figure 9. Cytotoxicity assay of HC PBMC, patient PBMC, LIL and TIL cells. A, B): Frequency of CFSE+LIVE/DEAD (LD)+ HuCCT-1 cell line targets when HC PBMC (n = 5), patient PBMC (n = 10), LIL (n = 8) and TIL (n = 5) were used as effector cells in the presence of 7C6 mAb and isotype control (IgG1). The parametric paired t tests were used to compare data. C, D): Frequency of CFSE+LD+ patient-derived cell line targets when HC PBMC (n = 5), patient PBMC (n = 8), LIL (n = 8) and TIL (n = 4) were used as effectors in the presence of 7C6 and isotype control. The parametric paired t test was used to compare data in panel C. The non-parametric Wilcoxon t test was used to compare paired data in panel D. Target cell death was determined as frequency of CFSE+LD+ cells.

Article Snippet: The recombinant human IgG1 Fc (BioXcell, Lebanon, NH, USA) and the humanized anti-MICA/B 7C6-IgG1 mAb were added at a final concentration of 10 μg/ml.

Techniques: Cytotoxicity Assay, Control, Derivative Assay

Journal: Journal of Translational Medicine

Article Title: N-acetyltransferase 10 affects the proliferation of intrahepatic cholangiocarcinoma and M2-type polarization of macrophages by regulating C-C motif chemokine ligand 2

doi: 10.1186/s12967-024-05664-z

Figure Lengend Snippet: NAT10 polarizes macrophages toward the M2 type through CCL2 . (A) Macrophages were polarized by treating them with the supernatant of ICC cells for 24 h. (B) After co-culturing ICC cells and macrophages for 24 h, the macrophages underwent polarization. (C) Co-culturing ICC cells with macrophages for 24 h resulted in the polarization of macrophages towards the M2 phenotype. (D) Immunofluorescence showed that CD86 expression increased and CD163 expression decreased in NAT10-knockdown tumors ( n = 6). Scale bars: 50 μm. (E and F) Western blot and ELISA showed that NAT10 knockdown decreased CCL2 expression levels in ICC cells and cell supernatant. (G) CCL2-knockdown cell lines were constructed and verified at the protein level. (H) Flow cytometry confirmed that CCL2 knockdown reduced the polarization of macrophages toward M2. (I) Immunofluorescence showed that CD86 expression increased and CD163 expression decreased in CCL2-knockdown tumors ( n = 6). Scale bars: 50 μm. Data are representative of three or more independent experimental replicates. Data are displayed as the mean ± SD. P -values were determined by Student’s t-test and one-way ANOVA in panels. * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001. ICC, intrahepatic cholangiocarcinoma; ELISA, enzyme-linked immunosorbent assay; SD, standard deviation; ANOVA, analysis of variance

Article Snippet: The levels of CCL2 in the cell supernatants were determined using an enzyme-linked immunosorbent assay (ELISA) kit (E-EL-H6005, Elabscience).

Techniques: Immunofluorescence, Expressing, Knockdown, Western Blot, Enzyme-linked Immunosorbent Assay, Construct, Flow Cytometry, Standard Deviation

Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)

Article Title: Bone Marrow Mesenchymal Stem Cell-Derived Dermcidin-Containing Migrasomes enhance LC3-Associated Phagocytosis of Pulmonary Macrophages and Protect against Post-Stroke Pneumonia.

doi: 10.1002/advs.202206432

Figure Lengend Snippet: Figure 7. DCD is beneficial to AIS recovery and DCD-containing BM-MSC-derived migrasome effectively promotes phagocytosis of macrophages. A– G) Peripheral blood of AIS patients (acute phase, 0–3d after disease onset, n = 16) and healthy controls (HC, n = 8) were collected. (A) Plasma DCD concentration was assessed with ELISA. *p < 0.05, compared with HC by Student’s t-test (mean ± standard deviation). (B) Correlation of clinic parameters and plasma DCD concentration was assessed with Spearman correlation analysis and Point-biserial correlations. *p < 0.05. DM, diabetes mellitus, CHD, coronary heart disease. (C) Representative images of the magnetic resonance diffusion weighted imaging (MR-DWI) of AIS patients with low plasma DCD concentration (DCD ≤3.33 ng ml−1) or high plasma DCD concentration (DCD > 3.33 ng ml−1). (D) Association between plasma DCD concentration with infarct scale was estimated with Spearman correlation analysis. (E) Association between plasma DCD concentration with delta NIHSS (NIHSS at 7d minus NIHSS at 1d) was estimated with Spearman correlation analysis. (F) Representative images of the chest Computed Tomography (CT) of AIS patients with low plasma DCD concentration (DCD ≤3.39 ng ml−1, median of the cohort) or high plasma DCD concentration (DCD > 3.39 ng ml−1, median of the cohort). (G) Pie charts showing the occurrence of post-stroke pneumonia in AIS patients with low and high plasma DCD concentrations. H) DCD (1 ng ml−1), PBS-migrasomes (PBS-M, 50 μg ml−1) or E. Coli-migrasomes (E. Coli-M, 50 μg ml−1) labeled with Dil (red) were treated to BMDM (15 min). Immunostaining of WGA (green) and DCD (withe) in migrasome-treated BMDM was performed. Experiments were repeated for three times. I,J) BMDM were first pre-stimulated with DCD (1 ng ml−1), PBS-M (50 μg ml−1), or E. Coli-M (50 μg ml−1) for overnight then treated with E. Coli (E. Coli : BMDM = 20:1, 1 h). Phagocytic efficiency of BMDM to GFP expressing E. Coli was assessed with flow cytometry (I) and immunostaining (J). Experiments were repeated three times. **p < 0.01, compared with PBS-treated group by one-way ANOVA (mean ± standard deviation).

Article Snippet: Human Monocyte Enrichment and Macrophage Differentiation: Mononucleus cells were isolated from peripheral blood of healthy adults (age = 18–40y) with human peripheral blood monocyte isolation Solution kit (Solarbio, P8680).

Techniques: Derivative Assay, Clinical Proteomics, Concentration Assay, Enzyme-linked Immunosorbent Assay, Standard Deviation, Imaging, Computed Tomography, Labeling, Immunostaining, Expressing, Cytometry